Results 31 to 40 of about 2,034 (179)
Intracellular NAD+ Depletion Confers a Priming Signal for NLRP3 Inflammasome Activation
Frontiers in Immunology, 2021 Nicotinamide adenine dinucleotide (NAD+) is an important cofactor in many redox and non-redox NAD+-consuming enzyme reactions. Intracellular NAD+ level steadily declines with age, but its role in the innate immune potential of myeloid cells remains ...
Do-Wan Shim +6 more
doaj +1 more source
Neoplasia: An International Journal for Oncology Research, 2023 Nicotinamide phosphoribosyltransferase (NAMPT) is a key metabolic enzyme in NAD+ synthesis pathways and is found upregulated in several tumors, depicting NAD(H) lowering agents, like the NAMPT inhibitor FK866, as an appealing approach for anticancer ...
Agata Sofia Assuncao Carreira +13 more
doaj +1 more source
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. [PDF]
PLoS ONE, 2009 Nicotinamide phosphoribosyltransferase (Nampt) inhibitors such as FK866 are potent inhibitors of NAD(+) synthesis that show promise for the treatment of different forms of cancer.
Santina Bruzzone +18 more
doaj +1 more source
Frontiers in Oncology, 2022 Anaplastic meningioma is classified as a World Health Organization (WHO) grade III tumor and shows a strong tendency to recur. Although the incidence of anaplastic meningioma is low, the high rate of recurrence and death still makes treatment a challenge.
Yuxuan Deng +11 more
doaj +1 more source
Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [PDF]
FEBS Open BioWe analyzed alterations of PAR metabolism‐related proteins in PARG inhibitor‐resistant HCT116RPDD cells. Although PARG levels remained unchanged, HCT116RPDD cells exhibited reduced PARP1 and ARH3 expression and elevated PAR levels. Interestingly, HCT116RPDD cells exhibited slightly elevated intracellular NAD+/NADH and ATP levels. Our findings suggest a
Tsuda K, Ogino Y, Sato A.
europepmc +2 more sources
The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells
Cancers, 2022 Pancreatic cancer (pancreatic ductal adenocarcinoma: PDAC) is one of the most aggressive neoplastic diseases. Metformin use was associated with reduced pancreatic cancer incidence or better survival in diabetics. Metformin has been shown to inhibit PDAC cells survival and growth in vitro and in vivo.
Maxime Parisotto +11 more
openaire +2 more sources
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery
Pharmaceuticals, 2022 Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase
Moustafa S. Ghanem +14 more
doaj +1 more source
NAD+ Acts as a Protective Factor in Cellular Stress Response to DNA Alkylating Agents
Cells, 2023 Sulfur mustard (SM) and its derivatives are potent genotoxic agents, which have been shown to trigger the activation of poly (ADP-ribose) polymerases (PARPs) and the depletion of their substrate, nicotinamide adenine dinucleotide (NAD+).
Joanna Ruszkiewicz +10 more
doaj +1 more source
Respiratory Research, 2017 Background Emerging evidence reveals that nicotinamide phosphoribosyltransferase (NAMPT) has a significant role in the pathophysiology of the inflammatory process.
Geng-Chin Wu +7 more
doaj +1 more source
Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells. [PDF]
PLoS ONE, 2014 Nicotinamide phosphoribosyltransferase (NAMPT) plays an important role in cellular bioenergetics. It is responsible for converting nicotinamide to nicotinamide adenine dinucleotide, an essential molecule in cellular metabolism. NAMPT has been extensively
Vladimir Tolstikov +4 more
doaj +1 more source